A Mexican-made anti-venin that helps children recover from life-threatening reactions to scorpion stings has received U.S. approval, officials said. The U.S. Food and Drug Administration has approved the antidote Anascorp to treat serious reaction to the stings of bark scorpions, common throughout Arizona and considered a major threat to young children, the Arizona Republic reported Thursday. The scorpions\' painful stings can cause children to lose muscle control and can lead to breathing difficulties. About 8,000 scorpion stings are reported in Arizona each year, with several hundred serious enough to require medical attention. \"This is a great triumph,\" said Dr. Leslie Boyer, a University of Arizona pediatrician who spearheaded clinical trials of the anti-venin. Mexican company Instituto Bioclon produces Anascorp from the plasma of horses immunized with scorpion venom. The company agreed to open its operations to the FDA\'s rigorous inspection process to ensure its manufacturing practices meets the agency\'s standards, Boyer said. The approval of Anascorp is the first time the FDA has approved a drug developed and made in Latin America, she said.
GMT 14:01 2018 Thursday ,30 August
Expat with rare heart disorder gets life-saving surgeryGMT 00:18 2018 Tuesday ,23 January
Boy with 10-pound tumour on face diesGMT 21:23 2018 Monday ,22 January
All set for first global medical tourism conference in DubaiGMT 22:46 2018 Sunday ,21 January
Second face transplant for FrenchmanGMT 07:51 2018 Saturday ,20 January
Trio aquitted of negligence in Canada railway disasterGMT 10:57 2018 Thursday ,18 January
Breastfeeding for 6 months cuts diabetes risk in half: studyGMT 16:10 2018 Wednesday ,17 January
Child mummy in Italy had hepatitis, not smallpoxGMT 18:36 2018 Tuesday ,16 January
Greece strikes cause transport chaos, healthcare delaysMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor